Expert Interview
A look at the results from the Phase 3b FRONTIER5 trial, which evaluated a direct switch from emicizumab to Mim8 (denecimig) prophylaxis in adults and adolescents with hemophilia A, with or without inhibitors.
Ticker(s): NVO.
What are your impressions of the FRONTIER5 trial data, particularly the tolerability and safety profile of Mim8 when switching directly from emicizumab without a washout period?
Added By: sara_adminHow might the extended dosing interval and stronger potency of Mim8 influence your clinical decision-making compared to existing options like emicizumab?
Added By: sara_adminWhat patient characteristics or clinical factors would make you more or less likely to consider switching a stable patient from emicizumab to Mim8, if approved?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
